Daunorubicin dnr

The AML cell lines U937, MOLM-14, MV4-11, HL60, HEL, THP-1, NOMO-1, OCI-AML2, OCI-AML3 and NB4 were provided by collaborators or were purchased from ATCC or DSMZ (Braunschweig, Germany). All cell lines were cultured in RPMI-1640 medium containing 10% FBS (GIBCO, Life Technologies, Carlsbad, CA, USA), 2 μM l−1 glutamine, 100 U mL−1 penicillin, and 100 μg ml−1 streptomycin (GIBCO, Life Technologies, Carlsbad, CA, USA). The 293T cell line was purchased from ATCC and cultured in DMEM containing 10% FBS (GIBCO, Life Technologies, Carlsbad, CA, USA), 2 μM l−1 glutamine, 100 U mL−1 penicillin, and 100 μg mL−1 streptomycin (GIBCO, Life Technologies, Carlsbad, CA, USA). Daunorubicin (DNR) and cytarabine (ARA-C) were purchased from Selleck Chemicals LLC (Houston, TX, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively; SIRT6 chemical inhibitor [2,4-dioxo-N-(4-(pyridin-3-yloxyphenyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide, henceforth named compound 1] was obtained from MolPort (Riga, Latvia).

In vitro drug sensitivity to therapeutic agents was assessed with CCK-8 as previously described (20 (link)). Cells were exposed to different concentration gradients of chemotherapeutic agents [including vincristine (VCR; 10, 20, 30, 40 and 50 µg/l; Selleck Chemicals), daunorubicin (DNR; 10, 20, 30, 40 and 50 µg/l; Selleck Chemicals), cyclophosphamide (CPM; 50, 100, 200, 400, 600, 800 and 1,000 µg/ml; Selleck Chemicals), dexamethasone (DXM; 0.5, 1, 1.5, 2 and 2.5 nmol/l; Selleck Chemicals) or imatinib (10, 20 and 30 µmol/l; Sigma-Aldrich; Merch KGaA) at 37°C for 48 h, and CCK-8 was used to determine the cell viability. Optical density (OD) values were measured at 450 nm using a SpectraMax M5 microplate reader (Molecular Devices, LLC). The cytotoxicity was calculated using the following formula: Cytotoxicity (%)=(1-mean OD of treated/mean OD of control) ×100.